ALNY AI Stock Analysis – Buy, Hold, or Avoid?
Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam (ALNY) offers a compelling long-term growth story with strong fundamentals and positive sentiment, but its current valuation is stretched and technicals are neutral, making timing critical. The stock is best suited for risk-tolerant investors willing to weather volatility and potential multiple contraction. Short-term caution is warranted, but long-term prospects remain attractive if execution continues.
Fundamentals
Alnylam Pharmaceuticals (ALNY) has executed a dramatic turnaround in profitability and growth, transitioning from multi-year net losses to robust profitability in 2025, underpinned by strong revenue expansion and improving operating leverage. The company is capitalizing on its RNAi platform with a growing portfolio of commercialized drugs, supporting increased investor confidence, though its current valuation reflects considerable forward optimism.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
84.95% YoY
Q4 2025
Net Income
322.56% YoY
Q4 2025
Net Margin
Q4 2025
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q4 2025
Net Income Growth YoY
Latest Quarter: Q4 2025
Revenue Per Share Growth YoY
Latest Quarter: Q4 2025
EPS Growth YoY
Latest Quarter: Q4 2025
Book Value Per Share Growth YoY
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1B | 1.2B | 773.7M | 594.2M | 593.2M | 500.9M | 659.8M | 494.3M |
| Revenue Growth YoY | +84.95% | +149.35% | +17.26% | +20.20% | +34.90% | -33.26% | +107.00% | +54.82% |
| Net Income | 186.4M | 251.1M | -66.3M | -57.5M | -83.8M | -111.6M | -16.9M | -65.9M |
| Net Income Growth YoY | +322.56% | +325.05% | -292.43% | +12.82% | +39.24% | -175.51% | +93.88% | +62.13% |
| EPS | $1.41 | $1.91 | -$0.51 | -$0.44 | -$0.65 | -$0.87 | -$0.13 | -$0.52 |
| EPS Growth YoY | +316.92% | +319.54% | -292.31% | +15.38% | +40.91% | -173.73% | +94.12% | +62.86% |
Profitability Metrics
Gross Margin
TTM
Operating Margin
TTM
Net Margin
TTM
Return on Equity
TTM
Return on Assets
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.60% | 84.21% | 81.52% | 88.04% | 82.67% | 82.85% | 89.59% | 86.65% |
| Operating Margin | 12.01% | 29.46% | -2.09% | 3.04% | -17.73% | -15.35% | 7.37% | -8.79% |
| Net Margin | 16.99% | 20.10% | -8.57% | -9.67% | -14.12% | -22.27% | -2.56% | -13.34% |
| Return on Equity (ROE) | 23.62% | 107.35% | -26.45% | -49.79% | -124.86% | -344.84% | 550.67% | 30.07% |
| Return on Assets (ROA) | 3.75% | 5.18% | -1.45% | -1.36% | -1.98% | -2.65% | -0.42% | -1.72% |
Technical Analysis
Technical indicator data for ALNY is currently unavailable due to API issues. However, utilizing web search to gather recent technical insights and chart data will provide a comprehensive trading analysis focused on price trends and momentum.
No extreme reading
Price in downtrend
Strong trend active
50 below 200 - bearish
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Alnylam Pharmaceuticals (ALNY) has executed a dramatic turnaround in profitability and growth, transitioning from multi-year net losses to robust profitability in 2025, underpinned by strong revenue expansion and improving operating leverage. The company is capitalizing on its RNAi platform with a growing portfolio of commercialized drugs, supporting increased investor confidence, though its current valuation reflects considerable forward optimism.
Latest Earnings
Q4 2025 Earnings (Dec 30, 2025)
Earnings Per Share (EPS)
Actual
$0.82
Estimated
$1.16
Surprise
$-0.34
Surprise %
-29.31%
Revenue
Actual
$1.1B
Estimated
$1.15B
Surprise
-$52.08M
Surprise %
-4.53%
Historical Earnings
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $0.82 | $2.90 | $0.32 | $-0.01 | $0.06 | $-0.50 | $0.56 | $-0.16 |
| EPS (Estimated) | $1.16 | $0.56 | $-0.54 | $-0.89 | $-0.62 | $-0.92 | $-1.07 | $-1.12 |
| EPS Surprise | -$0.34 | +$2.34 | +$0.86 | +$0.88 | +$0.68 | +$0.42 | +$1.63 | +$0.96 |
| % Diff | -29.3% | +416.9% | +158.9% | +98.9% | +109.7% | +45.5% | +152.3% | +85.7% |
| Revenue | ||||||||
| Revenue (Actual) | $1.1B | $1.25B | $773.69M | $594.19M | $593.17M | $500.92M | $659.83M | $494.33M |
| Revenue (Estimated) | $1.15B | $959.4M | $662.87M | $585.14M | $582.61M | $532.91M | $447.22M | $428.01M |
| Revenue Surprise | -$52.08M | +$289.63M | +$110.82M | +$9.05M | +$10.56M | -$31.99M | +$212.6M | +$66.33M |
| % Diff | -4.5% | +30.2% | +16.7% | +1.5% | +1.8% | -6.0% | +47.5% | +15.5% |
Valuation
Alnylam Pharmaceuticals (ALNY) is trading at a substantial premium relative to biotech industry averages, driven by robust revenue growth and strong future earnings projections. Despite some volatility in profitability and elevated leverage in previous quarters, the company's fundamentals reflect improving margins and solid profitability, which justify a higher valuation multiple. Analyst consensus is generally bullish, with significant upside potential indicated by price targets well above current levels.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 70.52 | 59.68 | -159.50 | -152.30 | -90.31 | -79.25 | -456.46 | -73.33 |
| Price to Sales | 47.93 | 47.99 | 54.66 | 58.93 | 51.01 | 70.60 | 46.73 | 39.12 |
| Price to Book | 66.63 | 256.27 | 168.75 | 303.33 | 451.03 | 1093.10 | -10054.34 | -88.20 |
| Enterprise Value to EBITDA | 359.47 | 201.09 | 2331.78 | 3205.39 | -227.35 | -613.42 | 878.21 | -1440.45 |
| Enterprise Value to Revenue | 47.59 | 47.84 | 56.76 | 61.79 | 54.01 | 73.85 | 49.37 | 43.18 |
Sentiment & Analyst Ratings
Alnylam Pharmaceuticals (ALNY) currently enjoys a generally positive market sentiment, supported by strong revenue growth, a robust product pipeline, and bullish analyst ratings with significant upside price targets. The company’s recent developments, including positive trial data and strategic growth initiatives, keep investor confidence high despite some concerns over competition and pricing pressures. Social media sentiment aligns broadly with analyst optimism, though cautious voices highlight the risks inherent in commercial execution and market competition.
Analyst Recommendations
Risk Assessment
Alnylam Pharmaceuticals presents a moderate to high-risk investment profile characterized by robust liquidity but a capital structure with elevated debt-to-equity levels that have improved recently. The company benefits from strong revenue growth in its RNAi franchise, supported by promising product momentum and a strategic focus on pipeline expansion, but it faces significant risks tied to product concentration, competitive pressures, and regulatory complexities.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q4 2025
Quick Ratio
Latest Quarter: Q4 2025
Debt-to-Equity
Latest Quarter: Q4 2025
Debt-to-Assets
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 2.76 | 2.54 | 2.80 | 3.04 | 2.78 | 2.75 | 3.01 | 3.17 |
| Quick Ratio | 2.71 | 2.49 | 2.75 | 2.98 | 2.71 | 2.69 | 2.93 | 3.07 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 1.62 | 5.59 | 10.93 | 23.58 | 40.89 | 84.26 | -883.03 | -12.24 |
| Debt-to-Assets | 0.26 | 0.27 | 0.60 | 0.65 | 0.65 | 0.65 | 0.68 | 0.70 |
Liquidity Assessment
Current Ratio: 2.76(Strong)
Quick Ratio: 2.71(Strong)
The company has strong liquidity with sufficient short-term assets to cover liabilities.
Solvency Assessment
Debt-to-Equity: 1.62(High)
Debt-to-Assets: 0.26(Low)
The company has relatively high debt levels, which may increase financial risk in economic downturns.
Frequently Asked Questions about ALNY
AI Answers: Common Questions About ALNY
Get AI-powered answers to the questions investors ask most about Alnylam Pharmaceuticals, Inc.
ALNY is not a clear buy at current levels for most investors due to its very high P/E (137.85) and price near $321, which already prices in substantial growth. However, for long-term investors confident in the RNAi platform and pipeline, it remains attractive if willing to accept volatility and potential short-term downside.
If you are a short-term trader, consider waiting or trimming as technicals are neutral and valuation is stretched. Long-term holders should maintain positions unless there is a fundamental deterioration, as the growth story and pipeline remain intact.
The biggest risks are premium valuation (P/E 137.85, debt/equity 1.62), execution on new product launches, and sector volatility. Tight interest coverage (~1.0) and reliance on a few key franchises add to the risk profile.
Analyst consensus targets imply 35-45% upside from current levels, with resistance near $335 and support at $310. Technicals suggest waiting for a breakout above $335 or a pullback to $310-$315 for better entry.
ALNY is overvalued relative to biotech peers, with P/E and EV/EBITDA multiples far above sector averages (P/E sector avg: low-mid 20s). The premium is only justified if rapid growth and pipeline success continue.
Fundamentals are strong: revenue up 65% YoY, gross margins above 80%, and net margin positive at 8.4%. The company has transitioned to profitability and maintains robust liquidity (current ratio >2.7), but high R&D spend and leverage remain.
Technical indicators are neutral; price is consolidating between $310 and $335 with no clear trend. Momentum is lacking, so traders should wait for a decisive move before entering.
Key catalysts include upcoming Phase 3 trial data, new drug approvals, earnings releases, and progress on the 'Alnylam 2030' strategy. Positive news on pipeline assets or international expansion could trigger upside.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.